Macquarie initiated coverage of Pediatrix Medical (MD) with an Outperform rating and $18 price target Pediatrix Medical owns physician groups that staff and manages roughly one-quarter of hospital-based Neonatal Intensive Care Units in the U.S., notes the analyst. The firm considers valuation “attractive” as fundamentals stabilize and concerns around surprise billing legislation subsides, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Announces Leadership Transition of Dr. Pickert
- Pediatrix Medical price target raised to $15 from $13 at Mizuho
- Pediatrix Medical price target raised to $18 from $14 at Jefferies
- Pediatrix Medical price target raised to $15 from $10 at Leerink
- Pediatrix Medical price target raised to $16 from $13 at Truist